Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Cell to Cure ApS
APS
Active
Advertising protection
CVR 39401975
Kajerødgård 9, 3460
Birkerød
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 8 years old
14 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Cell to Cure ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
-3M
2024
-3M
2025
EBITDA
DKK millions
0M
-4M
-8M
-11M
-15M
0M
2021
-1M
-100%
2022
-2M
-100%
2023
-9M
-350%
2024
-12M
-33%
2025
Income statement
DKK thousands
Item
2021
2022
2023
2024
2025
Gross profit
295
389
100
-2.803
-3.076
Staff expenses
-0
-1.047
-1.922
-6.385
-9.060
EBITDA
295
-658
-1.821
-9.187
-12.136
Depreciation & amort.
-0
-0
-0
-0
-367
EBIT
295
-658
-1.821
-9.187
-12.503
Net financials
-15
-14
-110
-52
-206
Profit before tax
280
-672
-1.931
-9.240
-12.709
Tax
62
-270
-398
-2.253
-2.916
Net profit
218
-402
-1.534
-6.987
-9.793
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
2025
Total assets
1.014
1.487
1.871
6.080
9.578
Equity
695
-366
-1.899
3.114
-1.179
Long-term debt
62
0
1.392
0
0
Short-term debt
258
1.853
2.353
2.966
10.757
Total debt
320
1.853
3.746
2.966
10.757
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-1213616400.0%
This company
2021
2025
Equity ratio
-12.3%
This company
38.2%
Market median
-132% vs market
2021
2025
Return on equity
-979260400.0%
This company
18.4%
Market median
-5322067491% vs market
2021
2025
Net profit margin (of gross profit)
-979260400.0%
This company
2021
2025
Asset turnover (of gross profit)
-0.32×
This company
2021
2025
Debt / equity
9.12×
This company
0.62×
Market median
-1371% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-09-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-09-01 – 2023-08-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-09-01 – 2022-08-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2020-09-01 – 2021-08-31
View
PDF
More on Cell to Cure ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
